Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rakesh Jain
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Xtuit Pharmaceuticals, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Jain is a co-founder of Xtuit Pharmaceticals, Inc. The goal of Xtuit is to improve delivery and efficacy of drugs by alleviating desmoplasia. The company plans to use a number of agents, including angiotensin receptor blockers, to accomplish this goal. The Co-Chairs of Partners HealthCare Conflicts of Interest Committee evaluated the financial interest in connection with this research and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Integrative Pathophysiology of Solid Tumors
RELEVANCE (See instructions): The proposed translational studies are extremely important and timely as they will advance our basic understanding of the tumor microenvironment as well as inform trial design and help interpret the data from our planned clinical trials with (i) plerixfor - an FDA-approved anti-CXCR4 agent - for glioblastoma, colorectal and liver cancer, (ii) with anti-ANG2 antibody for glioblastoma, and (iii) with FDA-approved angiotensin II receptor blockers for pancreatic cancer.
Filed on April 09, 2014.
Tell us what you know about Rakesh Jain's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Rakesh Jain filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | $20,000 - $39,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | $20,000 - $39,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | Xtuit Pharmaceuticals, Inc. | $5,000 - $9,999 |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | Value cannot be readily determined |
| Rakesh Jain | Massachusetts General Hospital | Conflict of Interest | XTuit Pharmaceticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.